ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 84 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2014. The put-call ratio across all filers is 0.72 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $102,415 | -60.0% | 104,505 | -43.2% | 0.00% | – |
Q2 2023 | $255,928 | -68.6% | 184,121 | -64.1% | 0.00% | – |
Q1 2023 | $815,987 | +49.7% | 513,199 | +486.5% | 0.00% | – |
Q4 2022 | $545,093 | +23.9% | 87,495 | +33.0% | 0.00% | – |
Q3 2022 | $440,000 | -7.4% | 65,766 | -11.8% | 0.00% | – |
Q2 2022 | $475,000 | +15.9% | 74,592 | -15.6% | 0.00% | – |
Q1 2022 | $410,000 | -47.3% | 88,413 | -43.1% | 0.00% | – |
Q4 2021 | $778,000 | -36.3% | 155,453 | +53.2% | 0.00% | – |
Q3 2021 | $1,222,000 | +121.0% | 101,448 | +288.3% | 0.00% | – |
Q2 2021 | $553,000 | -49.9% | 26,128 | -33.6% | 0.00% | – |
Q1 2021 | $1,104,000 | +13.9% | 39,357 | +5.6% | 0.00% | – |
Q4 2020 | $969,000 | -33.6% | 37,266 | -5.1% | 0.00% | – |
Q3 2020 | $1,459,000 | -18.2% | 39,249 | +12.9% | 0.00% | – |
Q2 2020 | $1,784,000 | +139.8% | 34,758 | +47.5% | 0.00% | – |
Q1 2020 | $744,000 | -46.1% | 23,561 | +1.8% | 0.00% | – |
Q4 2019 | $1,380,000 | +68.7% | 23,143 | +3.7% | 0.00% | – |
Q3 2019 | $818,000 | -74.0% | 22,328 | -67.0% | 0.00% | – |
Q2 2019 | $3,150,000 | +5.6% | 67,724 | -8.8% | 0.00% | – |
Q1 2019 | $2,982,000 | +118.5% | 74,269 | +150.2% | 0.00% | – |
Q4 2018 | $1,365,000 | +124.5% | 29,678 | +116.1% | 0.00% | – |
Q3 2018 | $608,000 | -81.6% | 13,735 | -83.7% | 0.00% | -100.0% |
Q2 2018 | $3,299,000 | -4.8% | 84,172 | +75.8% | 0.00% | 0.0% |
Q1 2018 | $3,464,000 | +22.5% | 47,875 | +11.5% | 0.00% | – |
Q4 2017 | $2,827,000 | +62.1% | 42,927 | +23.4% | 0.00% | – |
Q3 2017 | $1,744,000 | +18.6% | 34,781 | +9.4% | 0.00% | – |
Q2 2017 | $1,471,000 | +103.5% | 31,783 | +55.2% | 0.00% | – |
Q1 2017 | $723,000 | -47.8% | 20,485 | -81.5% | 0.00% | – |
Q4 2016 | $1,384,000 | -6.9% | 110,523 | +2.9% | 0.00% | – |
Q3 2016 | $1,487,000 | +38.8% | 107,371 | -0.9% | 0.00% | – |
Q2 2016 | $1,071,000 | -39.5% | 108,381 | +3.5% | 0.00% | – |
Q1 2016 | $1,771,000 | -36.6% | 104,687 | -16.6% | 0.00% | -100.0% |
Q4 2015 | $2,795,000 | -19.9% | 125,569 | -15.1% | 0.00% | 0.0% |
Q3 2015 | $3,488,000 | -79.2% | 147,864 | -27.8% | 0.00% | -83.3% |
Q2 2015 | $16,744,000 | +347.2% | 204,796 | +406.5% | 0.01% | +500.0% |
Q1 2015 | $3,744,000 | +4357.1% | 40,432 | +1857.0% | 0.00% | – |
Q4 2014 | $84,000 | +1100.0% | 2,066 | +619.9% | 0.00% | – |
Q3 2014 | $7,000 | -50.0% | 287 | -68.3% | 0.00% | – |
Q2 2014 | $14,000 | +75.0% | 904 | +61.7% | 0.00% | – |
Q1 2014 | $8,000 | -81.0% | 559 | -81.6% | 0.00% | – |
Q4 2013 | $42,000 | +320.0% | 3,038 | +452.4% | 0.00% | – |
Q3 2013 | $10,000 | – | 550 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |